Cymbalta Withdrawal Symptoms: What to Expect and How to Manage Them
Author:
Blossom Editorial
Cymbalta (generic name duloxetine) is a medication belonging to a class of antidepressants called serotonin norepinephrine reuptake inhibitors (SNRIs).
It is used to treat depression, generalized anxiety disorder, fibromyalgia, and several chronic pain conditions. When people stop taking Cymbalta, especially abruptly, or reduce the dose too quickly, many experience a cluster of temporary symptoms known as antidepressant discontinuation syndrome.
Dizziness, nausea, flu-like aches, sleep problems, and strange electrical sensations in the head are among the most commonly reported.
These symptoms can be genuinely unpleasant, and they catch a lot of people off guard. They are also well documented and generally temporary. A slow, planned taper can substantially reduce the risk and severity of discontinuation symptoms, although it does not eliminate the possibility. Understanding what is happening and why makes the process considerably easier to navigate.
Key Takeaways
Discontinuation symptoms are common and usually temporary: Research suggests a meaningful share of people who stop an antidepressant experience symptoms specifically attributable to stopping the medication. For most people, these are mild to moderate, begin within a few days, and resolve within one to two weeks, although some may experience symptoms for longer.
Cymbalta’s short half-life is part of the reason: Duloxetine clears the body in roughly half a day, so blood levels drop quickly once you stop taking the doses. Medications that leave the system quickly tend to produce more noticeable discontinuation symptoms than ones that taper themselves out slowly.
A gradual taper is the single most effective prevention step: The FDA prescribing information explicitly recommends reducing the dose gradually rather than stopping abruptly. Never stop or change your dose without your prescriber, and tell them if symptoms are severe or persistent.
What is Cymbalta Withdrawal?
The clinical term is antidepressant discontinuation syndrome. It refers to a set of physical and psychological symptoms that can appear after reducing or stopping an antidepressant that has been taken regularly, typically for at least four to six weeks.
The symptoms often appear to be related to the dose and duration of treatment; people who’ve taken higher doses of an antidepressant for longer periods may experience more severe symptoms.
It is worth being precise about language here, because the word “withdrawal” carries baggage. Antidepressants like Cymbalta are not addictive in the way that term usually implies.
They do not produce cravings, compulsive use, or the drug-seeking behavior that defines a substance use disorder. Drugs that create dependence or carry a risk of misuse are, in fact, regulated by the government and placed under a category called controlled substances. Cymbalta is not a controlled substance.
What happens when you discontinue Cymbalta is a physiological adjustment: your nervous system has adapted to consistent levels of serotonin and norepinephrine activity, the neurotransmitters modulated by the medication. When these levels change quickly, the system needs time to recalibrate.
That distinction matters because people sometimes conclude that discontinuation symptoms mean they were addicted, or that the medication was harmful. Neither conclusion is supported by evidence. The symptoms only indicate that the body noticed a change, which is a normal biological response.
Why Cymbalta in Particular?
Not all antidepressants are equally likely to cause discontinuation symptoms, and the differences are largely explained by pharmacology rather than by anything unique to a given brand.
Cymbalta (duloxetine) has an elimination half-life of roughly 12 hours. That means about half the drug is eliminated from your bloodstream every 12 hours once you stop taking it. Compare that with fluoxetine, which has a half-life measured in days and an active metabolite that lingers for weeks. Fluoxetine essentially tapers itself. Duloxetine does not.
Cymbalta also acts on two neurotransmitter systems rather than one, which means the adjustment period involves changes in both serotonin and norepinephrine signaling. A 2024 systematic review and meta-analysis in The Lancet Psychiatry found that duloxetine was associated with discontinuation symptoms in approximately 44% of patients who stopped the medication, placing it in a moderate-risk range, higher than fluoxetine (Prozac) and sertraline (Zoloft), but lower than venlafaxine (Effexor) and desvenlafaxine. Among antidepressants, paroxetine (Paxil), venlafaxine, and desvenlafaxine are consistently identified as the hardest to stop.
What Are the Symptoms of Cymbalta Withdrawal?
The FDA prescribing information for Cymbalta lists the symptoms that occurred in adult placebo-controlled trials at a rate of at least 1 percent and more often than with placebo. They fall into several recognizable groups.
Physical and Flu-Like Symptoms
Many people describe the experience as feeling like they are coming down with something.
Reported symptoms in this category include fatigue, headache, muscle aches, sweating, and general malaise. Nausea, vomiting, and diarrhea are also commonly reported. Because these overlap so heavily with an ordinary viral illness, people frequently misattribute them to a bug rather than to the medication change.
Dizziness and Balance Problems
Dizziness is the most frequently reported symptom after stopping Cymbalta, and it is often the most disruptive.
It can range from mild lightheadedness to a sense that the room shifts when you turn your head. Some people describe difficulty with balance or a feeling of being slightly off-center. This can affect driving and should be taken seriously.
Sensory Disturbances and Brain Zaps
Another distinctive symptom is a sensation people commonly call brain zaps: brief, jolt-like electrical feelings in the head, sometimes accompanied by a visual flicker or a sound. They are frequently triggered by moving your eyes or turning your head. Paresthesia, meaning tingling or pins-and-needles sensations, falls into the same category.
These sensations are unsettling but are not known to cause harm, and they resolve as the nervous system adjusts.
Mood and Sleep Changes
Irritability, anxiety, agitation, and low mood are commonly reported, as are insomnia and vivid or disturbing dreams. These symptoms are harder to interpret, because they can look like a relapse of the condition being treated. However, discontinuation symptoms and relapse are two different things.
Timing is the most useful clue. Discontinuation symptoms typically appear within a few days of a dose change and generally improve over one to two weeks.
When it happens, a relapse of depression or anxiety usually develops more gradually after treatment ends, over weeks or months, and does not resolve on its own. If restarting the previous dose relieves symptoms within a day or so, that points strongly toward discontinuation rather than relapse.
How Long Do Cymbalta Withdrawal Symptoms Last?
For most people, symptoms begin within two to four days of the last dose or a significant dose reduction, peak within the first week, and fade over roughly one to two weeks.
That is the typical course, not a guarantee. A minority of people report symptoms lasting considerably longer, and there is ongoing clinical discussion about prolonged discontinuation symptoms in some individuals. Factors that appear to influence duration include how long you took the medication, what dose you were on, how quickly you came off, and whether you have experienced discontinuation symptoms before.
For instance, in an older study including nine clinical trials of duloxetine for depression, more patients on 120 mg/day reported discontinuation-emergent adverse events (discontinuation symptoms) than those on lower doses.
Moreover, a majority of these symptoms (65%) resolved within seven days. Interestingly, in the scope of this study, a longer duration of treatment (more than 8-9 weeks) did not appear to be associated with a higher rate or severity of discontinuation symptoms.
If symptoms are still significant after several weeks, that is a reason to contact your prescriber rather than to wait it out. It may mean the taper needs to be slower, or that what you are experiencing is something other than discontinuation.
How to Taper Off Cymbalta Safely
Tapering is the part of this process you have the most control over, and it is where the evidence is clearest. The specifics belong to you and your prescriber, but the underlying principles are consistent.
Go Slower Than You Think You Need To
A systematic review of antidepressant discontinuation found that gradual tapering was associated with fewer discontinuation symptoms and, in some cohorts, a longer time to relapse compared with rapid discontinuation.
There is no single correct schedule. Some people do fine reducing over several weeks. Others need months. Neither is a moral achievement or a failure.
In some cases where discontinuation symptoms are severe, the provider may restart a dose of Cymbalta and slow down the taper further.
Understand the Formulation Constraint
Cymbalta is a delayed-release capsule available in 20, 30, and 60 mg strengths. The capsule is designed to be swallowed whole. The prescribing information advises that it should not be chewed or crushed, and that the contents should not be sprinkled on food or mixed with liquids, because doing so can affect the enteric coating that protects the drug from stomach acid.
This is a real practical limitation. It means the smallest available step down is 20 mg.
Because duloxetine has a relatively short half-life, alternate-day dosing may increase fluctuations in drug levels and is generally not preferred. Some clinicians may consider it in selected situations, but tapering decisions should always be individualized. This is a conversation to have with your prescriber, not something to attempt alone.
Track What is Happening
Keeping a simple daily log of symptoms and severity during a taper is genuinely useful. It helps you and your prescriber distinguish discontinuation symptoms from relapse, identify which dose steps were hardest, and make evidence-based decisions about pacing rather than guessing.
Time it Well
If you have a choice, starting a taper during a relatively stable stretch of life is easier than starting one in the middle of a crisis, a move, or a major deadline. This is not always possible, but when it is, it helps.
When to Contact Your Doctor
Most discontinuation symptoms are manageable at home with your prescriber’s guidance. Some situations warrant prompt contact.
Severe or worsening mood symptoms, including new or returning thoughts of self-harm. This is the most important item on this list and should never be waited on.
Dizziness severe enough to affect walking or driving, or any fall.
Symptoms that are not improving after two to three weeks, or that are getting worse rather than better.
Persistent vomiting or diarrhea that raises a risk of dehydration.
Any symptom that is interfering substantially with work, school, or caregiving.
If you are experiencing thoughts of suicide or self-harm, contact the 988 Suicide and Crisis Lifeline by calling or texting 988, or seek emergency care immediately.
Medical Disclaimer
This article is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or medication. Never stop or change the dose of a prescribed medication without consulting your prescriber first. If you are experiencing a mental health crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988.
Sources
U.S. Food and Drug Administration. (2023, August). Cymbalta (duloxetine delayed-release capsules) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf
Dhaliwal JS, Spurling BC, Molla M. Duloxetine. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549806/
Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024). Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. The Lancet Psychiatry, 11(7), 526–535. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00133-0/fulltext
Perahia, D. G., Kajdasz, D. K., Desaiah, D., & Haddad, P. M. (2005). Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of affective disorders, 89(1-3), 207–212. https://pubmed.ncbi.nlm.nih.gov/16266753/
Maund, E., Stuart, B., Moore, M., Dowrick, C., Geraghty, A. W. A., Dawson, S., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of family medicine, 17(1), 52–60. https://pmc.ncbi.nlm.nih.gov/articles/PMC6342590/
Cleveland Clinic. (2023, August 30). Antidepressant discontinuation syndrome: Symptoms. https://my.clevelandclinic.org/health/diseases/25218-antidepressant-discontinuation-syndrome
Hosenbocus, S., & Chahal, R. (2011). SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents. Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent, 20(1), 60–67. https://pmc.ncbi.nlm.nih.gov/articles/PMC3024727/
Quilichini JB, Revet A, Garcia P, et al. Withdrawal Syndrome Following Discontinuation of 28 Antidepressants: Pharmacovigilance Analysis of 31,688 Reports from the WHO Spontaneous Reporting Database. pubmed.ncbi.nlm.nih.gov
Gabriel, M., & Sharma, V. (2017). Antidepressant discontinuation syndrome. Canadian Medical Association Journal, 189(21), E747. https://www.cmaj.ca/content/189/21/E747
Hou, Y.-C., & Lai, C.-H. (2014). Long-term duloxetine withdrawal syndrome and management in a depressed patient. The Journal of Neuropsychiatry and Clinical Neurosciences, 26(1), E04. https://www.psychiatryonline.org/doi/10.1176/appi.neuropsych.12110265
Perahia, D. G., Kajdasz, D. K., Desaiah, D., & Haddad, P. M. (2005). Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. Journal of affective disorders, 89(1-3), 207–212. https://pubmed.ncbi.nlm.nih.gov/16266753/
National Institute of Mental Health. (2023, December). Mental health medications. U.S. Department of Health and Human Services, National Institutes of Health. https://www.nimh.nih.gov/health/topics/mental-health-medications
Sheffler, Z. M., Patel, P., & Abdijadid, S. (2026). Antidepressants. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK538182/
